Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
$36.62
-3.1%
$39.20
$26.20
$63.50
$1.74B1.43498,089 shs389,711 shs
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$16.85
-0.1%
$18.73
$13.52
$35.25
$1.71B2.222.47 million shs1.74 million shs
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
$2.21
+1.4%
$1.50
$0.69
$3.94
$439.54M0.825.13 million shs3.76 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$26.59
-2.2%
$32.90
$24.28
$55.33
$1.64B2.361.95 million shs1.54 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
-3.10%+0.74%-3.45%-0.81%-24.39%
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-0.06%+5.25%-15.45%+7.05%-35.32%
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
+1.38%+3.76%+50.34%+158.66%+30.00%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-2.21%+0.45%-23.35%-9.93%-39.80%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
3.871 of 5 stars
4.43.00.00.03.14.20.0
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
2.251 of 5 stars
3.50.00.00.02.92.50.6
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
3.7894 of 5 stars
3.41.00.03.92.51.70.6
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.9578 of 5 stars
3.42.00.04.42.80.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
2.88
Moderate Buy$97.29165.66% Upside
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
3.07
Buy$48.45187.56% Upside
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
2.80
Moderate Buy$7.00216.74% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.73
Moderate Buy$49.4085.78% Upside

Current Analyst Ratings Breakdown

Latest ESPR, APGE, BEAM, and TWST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/28/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/28/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$78.00 ➝ $87.00
8/14/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/11/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$90.00
8/6/2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$25.00 ➝ $21.00
8/4/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/4/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$46.00
7/21/2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/7/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
7/7/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$90.00
7/7/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$100.00 ➝ $115.00
(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
N/AN/AN/AN/A$13.43 per shareN/A
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$60.27M28.28N/AN/A$10.35 per share1.63
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
$332.31M1.34$0.02 per share90.73($2.15) per share-1.03
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$362.27M4.43N/AN/A$7.92 per share3.36
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
-$182.15M-$4.13N/AN/AN/AN/A-34.65%-32.76%11/11/2025 (Estimated)
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$376.74M-$4.50N/AN/AN/A-661.31%-43.15%-31.06%11/4/2025 (Estimated)
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
-$51.74M-$0.49N/AN/AN/A-35.84%-0.91%-28.41%11/6/2025 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$1.45N/AN/AN/A-23.51%-29.03%-21.77%11/17/2025 (Estimated)

Latest ESPR, APGE, BEAM, and TWST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
-$1.03-$1.13-$0.10-$1.13N/AN/A
8/5/2025Q2 2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$1.04-$1.00+$0.04-$1.00$13.29 million$8.47 million
8/5/2025Q2 2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
-$0.17-$0.02+$0.15-$0.02$62.55 million$82.39 million
8/4/2025Q3 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.54-$0.47+$0.07$0.33$95.52 million$96.06 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
N/AN/AN/AN/AN/A
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$0.905.34%N/AN/A N/A
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
N/A
16.36
16.36
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
N/A
6.75
6.75
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
N/A
1.15
0.76
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
3.90
3.60

Institutional Ownership

CompanyInstitutional Ownership
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
79.04%
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
99.68%
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
47.39%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
42.77%
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
3.50%
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
1.70%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
9146.11 million26.39 millionOptionable
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
510101.16 million97.62 millionOptionable
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
200201.62 million198.20 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99060.36 million58.54 millionOptionable

Recent News About These Companies

Twist Bioscience (TWST) Receives a Buy from Guggenheim
Twist Bioscience Appoints Trynka Shineman Blake to Board
Twist Bioscience: Headwinds Are Mounting

New MarketBeat Followers Over Time

Media Sentiment Over Time

Apogee Therapeutics stock logo

Apogee Therapeutics NASDAQ:APGE

$36.62 -1.17 (-3.10%)
Closing price 08/28/2025 04:00 PM Eastern
Extended Trading
$37.89 +1.27 (+3.47%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Beam Therapeutics stock logo

Beam Therapeutics NASDAQ:BEAM

$16.85 -0.01 (-0.06%)
Closing price 08/28/2025 04:00 PM Eastern
Extended Trading
$16.86 +0.00 (+0.03%)
As of 08:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Esperion Therapeutics stock logo

Esperion Therapeutics NASDAQ:ESPR

$2.21 +0.03 (+1.38%)
Closing price 08/28/2025 04:00 PM Eastern
Extended Trading
$2.23 +0.02 (+1.00%)
As of 08:32 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$26.59 -0.60 (-2.21%)
Closing price 08/28/2025 04:00 PM Eastern
Extended Trading
$26.58 -0.02 (-0.06%)
As of 08:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.